ReviewJournal of clinical medicine2025
PD-1 and PD-L1 Expression in Endometrial Cancer: A Systematic Review of the Literature.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Tumor-derived CCL20 activates tumor-associated neutrophils, predicting good prognosis in endometrial cancer.Translational cancer research · 2026Article
- Redefining the Treatment Landscape of Advanced Endometrial Cancer in the Era of Immunotherapy and Precision Oncology.Cancers · 2026Review
- A Single-Cell Atlas of Uterine Carcinosarcoma from Diverse Ancestries.bioRxiv : the preprint server for biology · 2026Article
- Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity.Advances in therapy · 2026Review
- Prognostic Significance of Immune Checkpoint Markers in Prognosis of Grade 3 Endometrioid Carcinoma.Medicina (Kaunas, Lithuania) · 2026Article
- Predictive biomarkers of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer.Therapeutic advances in medical oncology · 2026Review
- Genetics, genomics and clinical features of adenomatous polyposis.Familial cancer · 2025Review
- The dual nature of immunotherapy in female reproductive disorders: immune homeostasis and clinical challenges.Frontiers in immunology · 2025Review
- Immune Network Construction and Prognostic Evaluation of Checkpoint Genes in Endometrial Cancer Using STRING, MCODE, and GEPIA2.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.